Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example

Open Access

Peer-reviewed

Research Article

Mauricio Burotto ,

* E-mail: mauricio.burottopichun@nih.gov

Affiliation Medical Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America
⨯
Julia Wilkerson,

Affiliation Medical Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America
⨯
Wilfred Stein,

Affiliations Medical Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America, Hebrew University, Jerusalem, Israel
⨯
Robert Motzer,

Affiliation Memorial Sloan Kettering Cancer Institute, New York, New York, United States of America
⨯
Susan Bates,

Affiliation Medical Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America
⨯
Tito Fojo

Affiliation Medical Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America
⨯

Reader Comments (0)

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Renal cancer
Is the Subject Area "Renal cancer" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Renal cell carcinoma
Is the Subject Area "Renal cell carcinoma" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.